An interventional study of AKI Discharge Summary Template and Chat-Based Educational Messaging Program in Acute Kidney Injury and Acute Kidney Injury (AKI), sponsored by Northwell Health. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Northwell Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.
Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 76th largest by planned enrollment of the 237 interventional ones that give a count, is one of 29 that started in 2026, is one of 106 with no phase, reaches primary completion later than 22 of the 87 other live ones, and was the 361st registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
University of California, San Francisco · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Dana Fuhrman · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
370 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 69 · Phase 3 29 · Phase 4 23
First in 1999; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 67 across the 237 interventional studies, 124 across the 131 observational. Of the 240 that completed or were terminated, 84 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 370 have an industry lead sponsor. The 10 most frequent:
Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.
Northwell Health has 4 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
33 of the studies in Acute Kidney Injury with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161843Phase 3Ebima Clifford OkundayeUse of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | 2026-12-30 |
| NCT05399537Phase 3Vantive Health LLCSafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | 2027-01 |
| NCT05084196Phase 3Rutgers, The State University of New JerseyMelatonin for Prevention of Kidney Injury | 2027-06-01 |
| NCT07001098Stanford UniversityAmino Acids for Cardiac Surgery Associated AKI | 2026-11 |
| NCT07016074University of MichiganInorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury | 2026-11-30 |
Add all 33 to your calendar (.ics) → With an account.
Among the 370 studies in Acute Kidney Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether different ways of providing information and follow-up support after acute kidney injury, also called AKI, can improve care transitions for adults being discharged from the hospital. AKI is a sudden decrease in kidney function that can occur during a hospital stay.
The main questions this study aims to answer are:
Researchers will compare four groups:
Participants will complete questionnaires at the start of the study and about 4 weeks after hospital discharge. Participants will also receive a brief phone call about 3 months after discharge, and the research team will review their medical record for information about follow-up care, lab testing, emergency department visits, and hospital readmissions.
Acute kidney injury, also called AKI, is a common complication during hospitalization and is associated with increased risk of poor outcomes after discharge, including incomplete kidney recovery, medication-related safety concerns, emergency department visits, and hospital readmissions. Despite these risks, information about AKI and recommended follow-up care may not always be communicated clearly to patients or outpatient clinicians during the transition from hospital to home.
This pilot randomized clinical trial will evaluate the feasibility and preliminary effects of two care transition strategies for adults hospitalized with AKI. The strategies include an AKI discharge summary template designed to improve communication with outpatient clinicians, and a chat-based educational messaging program designed to provide patients with AKI-related information after discharge.
Participants will be assigned to one of four study groups: usual care, the AKI discharge summary template, the chat-based educational messaging program, or both the discharge summary template and chat-based messaging. The study will assess whether these strategies are feasible to deliver and acceptable to participants, and whether they improve patient knowledge, perceived preparedness, communication about AKI, and completion of recommended follow-up care after hospital discharge.
Participants will complete study questionnaires and allow the research team to review their medical records for information related to kidney function monitoring, follow-up care, emergency department visits, and hospital readmissions. The results of this pilot study will help inform the design of a larger future trial to improve care transitions for patients recovering from AKI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group will receive usual hospital discharge care. No additional study discharge summary template or chat-based educational messaging program will be provided as part of the intervention.
Participants in this group will receive usual hospital discharge care plus use of an AKI discharge summary template. The template is designed to support communication of AKI-related information and recommended follow-up care during the transition from hospital to outpatient care.
Behavioral: AKI Discharge Summary Template
Participants in this group will receive usual hospital discharge care plus access to a chat-based educational messaging program after hospital discharge. The program provides plain-language AKI education and follow-up support through a secure web-based chat-style interface.
Behavioral: Chat-Based Educational Messaging Program
Participants in this group will receive usual hospital discharge care plus both study interventions: use of the AKI discharge summary template and access to the chat-based educational messaging program after hospital discharge.
Behavioral: AKI Discharge Summary Template · Behavioral: Chat-Based Educational Messaging Program
The AKI discharge summary template provides structured AKI-related information for the hospital discharge summary, including information about the AKI episode and recommended follow-up care. The template is intended to improve communication during the transition from hospital to outpatient care.
The chat-based educational messaging program provides AKI-related educational messages after hospital discharge. Messages are delivered through a secure web-based chat-style interface and are designed to support patient understanding of AKI, post-discharge follow-up, and kidney-related care after hospitalization.
Feasibility: Eligible patient enrollment
Percentage of eligible patients enrolled among those approached.
Time frame: Enrollment period
Feasibility: Participant retention
Percentage of enrolled participants who complete the follow-up assessment.
Time frame: Baseline to 3 months after discharge
Feasibility: Successful delivery of assigned intervention components
Percentage of participants assigned to an intervention arm who receive the assigned intervention component or components as intended, including the AKI discharge summary template and/or chat-based educational messaging program.
Time frame: Hospital discharge through 4 weeks after discharge
AKI Knowledge Score
Participant AKI knowledge score measured using a study questionnaire. AKI knowledge is assessed using a 32-item questionnaire. Each item is scored as correct (1) or incorrect (0), yielding a total score ranging from 0 to 32. Higher scores indicate greater knowledge of acute kidney injury.
Time frame: 4 weeks after hospital discharge
Patient experience during care transitions
Patient-reported care transition experience measured using a validated transition-of-care instrument, such as the Care Transitions Measure-15. The Care Transitions Measure-15 (CTM-15) is a 15-item questionnaire assessing patient-reported quality of care transitions. Items are rated from 1 (strongly disagree) to 4 (strongly agree). The mean item score is transformed to a scale ranging from 0 to 100, with higher scores indicating better quality of care transitions.
Time frame: 4 weeks after hospital discharge
Self-management behaviors related to kidney health
Participant-reported self-management behaviors related to kidney health after hospital discharge, assessed using a study questionnaire. Kidney-related self-management behaviors and confidence are assessed using three study-developed items addressing: 1) fluid-intake monitoring as recommended; 2) avoidance of potentially kidney-harming medications unless approved by a healthcare provider; and 3) confidence recognizing symptoms requiring medical attention. Response options are "Yes," "No," and "I did not receive instructions." For each item, the percentage selecting each response will be calculated among participants who answered that item. Items are reported separately; no total score is calculated.
Time frame: 4 weeks after hospital discharge
Adherence to outpatient follow-up appointments
Percentage of participants who complete follow-up with a primary care provider or specialist after hospital discharge, assessed by participant report and/or medical record review.
Time frame: 4 weeks after hospital discharge, and 3 months after hospital discharge
Patient-reported discussion of AKI with outpatient provider
Percentage of participants who report discussing AKI or kidney-related follow-up needs with an outpatient provider after hospital discharge.
Time frame: 4 weeks after hospital discharge
Self-management behaviors related to kidney health
Participant-reported self-management behaviors related to kidney health after hospital discharge, assessed using a study questionnaire.
Time frame: 4 weeks after hospital discharge
Hospital readmission
Percentage of participants readmitted to the hospital after discharge from the index hospitalization.
Time frame: Within 4 weeks and within 3 months after hospital discharge
Kidney function trajectory after discharge
Kidney function status after hospital discharge, categorized as improved, stable, worsened, or requiring dialysis, based on available laboratory and clinical data.
Time frame: Within 4 weeks and within 3 months after hospital discharge
Plan to share: No — Individual participant data will not be shared at this time because this is a pilot feasibility study, and the dataset is expected to be small and potentially identifiable due to the clinical context, recruitment sites, hospitalization timing, and post-discharge care details. Aggregate study results may be shared through presentations and publications. The IPD sharing plan may be updated in the future if appropriate approvals, de-identification procedures, and data use agreements are established.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 6 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.